GlassScriptPhysician profile
Khalil Ibrahim Bourji
NPI 1184070815
$7,441.99
in general payments reported to CMS, 2019-2025
20 companies · $2,756 in 2025
The $2,756 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.36 · 2020: $145 · 2021: $54.82 · 2022: $1,334 · 2023: $1,583 · 2024: $1,515 · 2025: $2,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,777 · Education: $77.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,776.70 |
| Education | $77.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,866.10 | 2021-2025 | Rinvoq, Skyrizi, Mavyret |
| Amgen INC. | $900.82 | 2022-2025 | Tavneos, Otezla, Enbrel |
| Ani Pharmaceuticals, INC. | $817.80 | 2023-2025 | Purified Cortrophin Gel |
| Janssen Biotech, INC. | $805.21 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Ucb, INC. | $474.79 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $417.26 | 2019-2025 | |
| Glaxosmithkline, LLC. | $412.69 | 2023-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $348.62 | 2024-2025 | Acthar |
| Lilly USA, LLC | $99.86 | 2022-2025 | Taltz, Zepbound |
| Kyowa Kirin, INC. | $50.41 | 2023 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $40.96 | 2022 | |
| Sobi, INC | $33.96 | 2019-2020 | |
| Pfizer INC. | $32.84 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $25.81 | 2025 | |
| Alexion Pharmaceuticals, INC. | $24.72 | 2023 | Strensiq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.23 | 2025 | Hadlima |
| Radius Health, INC. | $19.25 | 2025 | Tymlos |
| Aurinia Pharma U.S., INC. | $17.93 | 2025 | Lupkynis |
| Sandoz INC. | $17.34 | 2025 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $15.39 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalil Ibrahim Bourji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.